Navigation Links
Kinase in Biological Technology

Sunesis Reports Financial Results for the Second Quarter 2009

... Idec (Nasdaq: BIIB ) for the selection of a Raf kinase inhibitor development candidate for the treatment ... in the co-development and co-promotion of the Raf kinase inhibitor resulting from this collaboration. ... them, and $1.5 million for the Biogen Idec Raf kinase inhibitor milestone referred to above. Revenues ...

Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

... a comprehensive global report on Small Molecule kinase Inhibitors market. World market for small molecule kinase inhibitor drugs is projected to reach $16.2 ... by the rising interest over the potential of kinase inhibitors in effectively blocking, and modifying ...

Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... monitoring has demonstrated inhibition of PI-3 kinase activity at doses as low as 1 mg per patient. ... patients, as well as clearcut inhibition of PI-3 kinase activity, even in the early cohorts in this dose ... kinase, which distinguishes it from other PI-3 kinase inhibitors currently in clinical development." ...

Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting

... protein in CML patients with resistance to kinase inhibitors." (Abstract No: 7026) Link to ASCO ... undescribed) mutations along the BCR-ABL tyrosine kinase that may constitute a new class of mutations that ... termination as a mechanism of resistance to kinase inhibitors." (Abstract No: 7028) Link to ASCO ...

Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis

... molecule inhibitor of phosphotidylinositol-3 kinase ("PI-3 kinase"), a key point of control of ... and growth, migration and metabolism. "PI-3 kinase is part of a signaling pathway that is believed ... These results suggest that inhibition of the PI-3 kinase pathway might be beneficial in such human lung ...

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

... in evaluating the mechanistic effects of kinase inhibitors like ENMD-2076 in cancer patients. ... is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of ...

Sigma-Aldrich Introduces Precisio(TM) Kinases for High-Throughput Screening and Kinase Profiling

... cell signaling. Optimized for high-throughput kinase screening and profiling, Precisio Kinases allow ... with Sigma's existing product lineup for kinase and phosphatase research, this new offering ... apoptosis and cell differentiation. Improper kinase function plays a role in many diseases, most ...

Telik Reports Preclinical Results at AACR Annual Meeting

... and carcinogenesis. Inhibition of Aurora kinase activity induces growth arrest and apoptosis in ... strong and equipotent inhibition of Aurora kinase and VEGFR kinase, with IC50s less than 10 nM. ... schedule. Drug inhibition of aurora kinase and VEGFR activity in tumor samples of treated ...

Cell Biosciences Introduces Kits for Oncoprotein Analysis

... signaling via MEK and ERK with a number of kinase inhibitor anticancer drugs. The Firefly ... in as few as 25 cells. Subtle effects of kinase inhibitor drugs on MEK and ERK phosphorylation ... a unique window into the specific actions of kinase inhibitor drugs in limited samples." ...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

... is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of ... tyrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are ...

SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor

... at a high frequency. Overexpression of Pim-1 kinase has been shown to be a marker of poor prognosis ... and sustained inhibition of Pim kinase targets in vivo following both single and ... transduction pathways. Transformation of Pim kinase in conjunction with other oncogenes is thought ...

SuperGen Reports 2008 Third Quarter Financial Results

... clinical advancement of MP-470, our oral tyrosine kinase inhibitor, and further preparations for entering SGI-1776, our oral PIM kinase inhibitor, into Phase 1 clinical trials." Total ... with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of ...

Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company

... of the important class of drugs known as kinase inhibitors. The Agreement with SUBC makes ... proprietary technologies in gene cloning, active kinase protein expression, protein purification ... products and services provided by Carna include kinase proteins, assay development ...

EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model

... of preclinical data for its Aurora A/angiogenesis kinase inhibitor, ENMD-2076. The data were presented by ... ) ENMD-2076 is a novel kinase inhibitor with potent activity against Aurora A ... a distinct profile of angiogenic tyrosine kinase targets. ENMD-2076 is currently in a phase 1 ...

SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy

... an orally bio-available multi-targeted tyrosine kinase inhibitor, showed encouraging tumor regression ... year-end, we expect to enter SGI-1776, our PIM kinase inhibitor, into Phase 1 clinical trials. This ... to oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of ...

Large-scale genetic study sheds new light on lung cancer

... cell receptors coupled to members of the tyrosine kinase family of enzymes, which are considered prime ... mutation affecting the mitogen-activated protein kinase (MAPK) pathway, indicating it plays a pivotal ... example, chemotherapy drugs known to inhibit the kinase insert domain receptor (KDR), such as sorafenib ...

S*BIO Completes US$26 Million Equity Financing

... U.S., SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is ...

SuperGen to Present Data at EORTC-NCI-AACR

... with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care ... vivo activity of SGI-1776, an orally active Pim kinase inhibitor Oct 23 ... 480: MP-470, a novel multi-targeted tyrosine kinase inhibitor targeting RAD 51 is not toxic to human ...

David Hsia, Ph.D. Joins Kinex Pharmaceuticals' Board of Directors

... to identify and develop peptide-competitive kinase inhibitors. The Company's clinical compound KX2-391 is a selective Src kinase inhibitor that is currently in Phase 1 trials for ... pipeline is focused on selective inhibitors for kinase targets that are important in oncology ...

GlaxoSmithKline and Cellzome Announce Major Strategic Alliance

... expertise in identifying and developing selective kinase inhibitors and its proprietary Kinobeads(TM) ... to license drug candidates from Cellzome's kinase programs directed against four ... concept for a product candidate for a particular kinase target, GSK would have an exclusive option ...

Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences

... protein kinases aiding the expansion of Caliper's kinase profiling and assay development services, and ProfilerPro kinase Selectivity Assay Kits. Caliper's products ... and use of Carna's products in the area of kinase inhibitor drug discovery -- a major focus of ...

SuperGen Reports 2008 Second Quarter Financial Results

... -- SGI-1776, our lead pre-clinical PIM kinase inhibitor, was found to cause tumor ... entitled, "A potent small molecule PIM kinase inhibitor with activity in cell lines from ... for the creation of small molecule PIM kinase inhibitors. SGI-1776 was identified as a ...

Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027

... for Atu027, but for any siRNA targeting protein kinase N beta. The notice is based on European patent ... directed to various aspects of the use of protein kinase N beta, the gene target of Atu027. Among others, ... Atu027, directed against protein kinase N beta for use in the treatment of numerous ...

Not the protein, but its location in the cell, determines the onset of leukemia

... are caused by genetic defects in which a certain kinase becomes too active − and this is the case ... most obvious solution is to make the carcinogenic kinase inactive, and so kinase inhibitors are usually used to combat these kinds ...

Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor

... ENMD-2076 is a novel, selective kinase inhibitor with potent activity against Aurora A ... and treating patients with our selective kinase inhibitor. We believe that this product candidate ... activity and our continuing interest in kinase inhibitors. In keeping with our 2008 goals of ...

CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform

... protein kinases and readily available kinase complex structures. Under the agreement, CRELUX ... expand an off-the-shelf crystal-grade protein kinase portfolio, optimized and quality-controlled for ... will grant CRELUX privileged direct access to kinase crystal-grade protein. “This new joint ...

Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization

... platform has become the new standard for kinase assays and we have broadened the platform to ... suite of solutions for Caliper's EZ Reader and kinase profiling customers," said Pyare Khanna, CEO of ... "Together, we are meeting the demand for GPCR and kinase lead optimization and profiling." About ...

SuperGen Reports 2008 First Quarter Financial Results

... MP-470, our clinical-stage tyrosine kinase (TK) inhibitor and Rad51 suppressor, and SGI-1776 ... are included below: -- SGI-1776, our lead PIM kinase inhibitor, was found to cause tumor ... entitled, "A potent small molecule PIM kinase inhibitor with activity in cell lines from ...

Mercury Therapeutics Patents Filed

... and specifically activate AMP activated protein kinase (AMPK). The compounds are strong candidates for ... candidates against a number of selected protein kinase drug targets in metabolic diseases and oncology. ... in Melbourne, Australia for AMP activated protein kinase (AMPK). In June 2001, MTI launched its R&D ...

Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences

... potency activators of AMP-activated protein kinase (AMPK), a well validated drug target for the ... in Melbourne, Australia for AMP activated protein kinase (AMPK). In June 2001, MTI launched its R&D ... candidates against a number of selected protein kinase drug targets in metabolic diseases and oncology. ...

SuperGen Reports 2007 Fourth Quarter and Annual Financial Results

... of MP470, a novel, oral, multi-targeted tyrosine kinase inhibitor (TKI)," said Dr. James Manuso, ... a clinical-stage multi-targeted tyrosine kinase inhibitor, demonstrates preclinical synergy ... and design of small molecule JAK2 and Pim kinase inhibitors (Posters C200, Abstract 907 and ...

JCI table of contents: Dec. 3, 2007

... (known as WBZ_4) that inhibited the tyrosine kinase behind GISTs (c-KIT) as effectively as imatinib did, and that neither inhibited the tyrosine kinase behind CML (BCR-Abl) nor had toxic effects on the ... of human cancer. TITLE: An anticancer C-Kit kinase inhibitor is reengineered to it more active and ...

Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

... AT7519 is a potent and selective Cyclin Dependent kinase (CDK) inhibitor currently in multi-centre Phase 1 ... Subtitle : Small Molecule Therapeutic Agents: kinase Inhibitors Session Time ... Poster Title: AT13148, an orally bioavailable AKT kinase inhibitor with potent anti-tumor activity in both ...

Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

... and on SNS-032, the company's cyclin-dependent kinase (CDK) inhibitor, currently in development for ... Session A -Small Molecule Therapeutic Agents: kinase Inhibitors Abstract No. A258 SNS-032 has ... trial in B-cell malignancies. SNS-314, an Aurora kinase inhibitor, is currently being studied in a Phase ...

Rigel to Present Research Programs at Scientific Conferences

... cancer targets including Axl receptor tyrosine kinase (Axl), Polo- like kinase 1 (PLK1) and Janus tyrosine kinase 2 (JAK2). Axl kinase is a novel therapeutic target for solid tumors. ...

Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours

... inhibits the protein-protein interaction between Raf-1 (key signalling kinase in the MAP kinase pathway) and Rb (retinoblastoma protein). Rb acts as a barrier to cell ...

Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models

... showed synergistic or additive effects when used together with tyrosine kinase inhibitors or chemotherapy in vitro in those cell lines. "AT-406 is ... with conventional chemotherapeutic and targeted agents (such as tyrosine kinase inhibitors) in preclinical tumor models. Other Research Including ...

Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.

... lead candidate, Telatinib, is a potent and highly selective oral tyrosine kinase inhibitor compound that targets pathways associated with the formation of ... 2009. ACT Biotech's second product candidate is the Multi-Mode kinase Inhibitor (ACTB1003), an oral anticancer compound that works via several ...

Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference

... for a "best in class" inhibitor. Cytopia is a world leader in JAK2 kinase chemistry and holds a broad range of JAK2 related patents. The main focus ... Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on ...

Cytopia Letter to Progen Shareholders

... studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the ... studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the ...
Other Contents
(Date:7/10/2014)... BLUE BELL, Pa. , July 2, 2014  Unisys ... The Netherlands , Unisys Nederland N.V., today announced that ... (DJI) to deliver, implement and manage a new Basic Provision ... . Unisys won the contract with a ... for identity management software. The term of the contract is ...
(Date:7/10/2014)... -- Fingerprint Cards, (FPC,s) new mobile touch sensor ... Chinese Top 5 smartphone OEM has selected FPC1021 for a ... October 2014.   FPC is proud to announce ... has a planned date for the start of mass production ... phone of 3 million units. The Chinese OEM wants to ...
(Date:7/10/2014)... belongs to the large, mainly tropical flowering plant family ... in the family rely on bees for their pollination. Only ... or vertebrates. The flowers of Axinaea appear in ... petals of the different species are pink, yellow, orange or ... the contrasting colours of their bulbous appendages. The pollination mechanism ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2Novel type of bird pollination mechanism discovered in South America 2
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Polio is history ... places like Afghanistan, Nigeria and Pakistan. Giving vaccinated children ... their immunity and help eradicate the highly infectious disease, ... is highly effective, immunity wanes as early as a ... be infected and contribute to the spread of the ...
(Date:7/11/2014)... breast cancer patients, the era of personalized medicine may ... by USC Stem Cell researcher Min Yu and scientists ... In a July 11 study in Science , ... cancer cells circulating through the blood streams of six ... "seeds" of metastasis, which travel to and establish secondary ...
(Date:7/11/2014)... FL (PRWEB) July 11, 2014 American ... on RFD-TV, next Tuesday, July 15, 2014, at 8:30 ... Sunbelt's line of proprietary products, which are designed and ... crops. Audiences will learn how these products help the ... environment in which it is grown. , The show ...
(Date:7/11/2014)... Shoulder instability is a common injury in ... has not been regularly determined following surgery. A new ... Medicine’s ( AOSSM ) Annual Meeting today details that ... no matter what the stabilization procedure (open vs. arthroscopic). ... to play following shoulder stabilization surgery. Age, number of ...
(Date:7/11/2014)... Anterior Cruciate Ligament (ACL) reconstructions occur more ... material used to create a new ligament may determine ... presenting their work today at the Annual Meeting of ... ). , “Our study results highlight that ... a donor) fail more frequently than using autografts (tissue ...
Breaking Medicine News(10 mins):Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:ACL Reconstructions May Last Longer With Autografts 2
Other TagsOther Tags